CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0562 (clinicaltrials.gov NCT No: NCT01891968)
Title:PHASE II STUDY OF SUBCUTANEOUS BORTEZOMIB FOR PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:Bortezomib
Study Status:Open
Study Description:The goal of this clinical research study is to learn if bortezomib can help to
control MDS. The safety of this drug will also be studied.

Bortezomib is designed to block a protein that causes cells to grow. This may
cause cancer cells to die.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Bortezomib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Millenium Pharamceuticals
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
Dept:Leukemia
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults